NASDAQ:CLDX Celldex Therapeutics Q2 2025 Earnings Report $23.61 +1.55 (+7.03%) Closing price 04:00 PM EasternExtended Trading$23.64 +0.04 (+0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Celldex Therapeutics EPS ResultsActual EPS-$0.85Consensus EPS -$0.86Beat/MissBeat by +$0.01One Year Ago EPSN/ACelldex Therapeutics Revenue ResultsActual Revenue$0.73 millionExpected Revenue$1.13 millionBeat/MissMissed by -$402.00 thousandYoY Revenue GrowthN/ACelldex Therapeutics Announcement DetailsQuarterQ2 2025Date8/7/2025TimeBefore Market OpensConference Call DateThursday, August 7, 2025Conference Call Time4:00PM ETUpcoming EarningsCelldex Therapeutics' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Monday, November 3, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Celldex Therapeutics Earnings HeadlinesCelldex’s Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic UrticariaAugust 29, 2025 | tipranks.comCelldex Therapeutics Advances Phase 3 Trial for Chronic Spontaneous Urticaria TreatmentAugust 27, 2025 | tipranks.comWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most.September 3 at 2:00 AM | Porter & Company (Ad)Celldex slides after Barzolvolimab hits target but fails to improve EoE symptoms in phase 2 trialAugust 20, 2025 | msn.comCelldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls ShortAugust 20, 2025 | benzinga.comLifeSci Capital Maintains a Buy on Celldex Therapeutics (CLDX), Keeps the PTAugust 20, 2025 | msn.comSee More Celldex Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Celldex Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celldex Therapeutics and other key companies, straight to your email. Email Address About Celldex TherapeuticsCelldex Therapeutics (NASDAQ:CLDX) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity. Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers. Other investigational compounds include varlilumab, an agonist antibody targeting CD27, CDX-301, a recombinant human Flt3 ligand designed to expand dendritic and immune cell populations, and CDX-1140, an antibody targeting CD40 to activate antigen-presenting cells. These programs are in various stages of clinical development, and Celldex collaborates with academic centers and industry partners to advance trials in the United States and select international sites. Founded in 1997 and headquartered in Hampton, New Jersey, Celldex has evolved from a small discovery lab into a specialized immunotherapy company. Under the leadership of President and Chief Executive Officer Roger F. Dansey, M.D., the organization has strengthened its scientific expertise and manufacturing capabilities to support both early-stage and later-stage development activities. Celldex serves patients primarily in North America while maintaining strategic relationships to facilitate broader access to its investigational therapies in other regions.Written by Jeffrey Neal JohnsonView Celldex Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles What to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive Earnings Upcoming Earnings Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
